Case Comprehensive Cancer Center: Weekly Newsletter

Home | Back to newsletter main page



November 14, 2011
CASE CCC IN THE NEWS Why Men and Women React Differently to Cancer Gene Bioidentical Hormone Health - Nov 14, 2011 Interestingly, Dr. Charis Eng, one of the lead researchers, has also made a link with why we are encouraged to drink red wine as a healthy daily preventive ... Champion of Integrative Oncology Brings International Conference Plain Dealer - Nov 9, 2011 ... therapies with more standard approaches, says Dr. Stanton Gerson, director of the UH Seidman Cancer Center and of the Case Comprehensive Cancer Center. ... Cleveland Clinic, UH Testing Therapies on Deadly Brain Tumors Plain Dealer - Nov 7, 2011 Dr. Andrew Sloan, director of the Brain Tumor and Neuro-Oncology Center at University Hospitals Case Medical Center, is overseeing three separate clinical ..."We've been slowly chipping away at glioblastomas over the last couple decades," said Dr. Gene Barnett, director of the Clinic's Burkhardt Brain Tumor ... On Sept. 7, neurosurgeon Dr. Michael Vogelbaum biopsied a small part of the tumor, then injected the retrovirus right onto the active tumor cells... Cancer Vaccines That Could Save Lives WZVN-TV - Nov 6, 2011 "Basically, your immune cells will go looking for prostate cancer cells," says Dr. Jorge Garcia, an oncologist with the Cleveland Clinic... "It's like weeds in a garden," says Vincent K. Tuohy, PhD. "You just can't get rid of every weed, and I thought it would be easier to get them before they take root."... MARK YOUR CALENDARS Cancer Center Seminar Series: Novel NFκB and STAT Signaling Pathways Present Novel Targets for Drug Development in Cancer Friday, November 18 12-1 pm Frohring Auditorium - BRB 105 Please join us Friday, November 18 at the next Cancer Center Seminar Series featuring George R. Stark, PhD, Staff and Distinguished Scientist in the Department of Molecular Genetics at the Cleveland Clinic Lerner Research Institute and Professor Emeritus in the Department of Genetics at Case Western Reserve University. In his presentation, Novel NFκB and STAT Signaling Pathways Present Novel Targets for Drug Development in Cancer, Dr. Stark will summarize recent progress and future plans on three topics: Proteins induced in response to the unphosphorylated form of the transcription factor STAT1 mediate resistance to DNA damage in many different cancers and also participate in the stepwise conversion of human mammary epithelial cells to tumors. The protein tyrosine kinase FER connects growth factor receptors to activation of the survival factor NFκB through a novel pathway involving tyrosine rather than serine phosphorylation. This pathway contributes to resistance to receptor tyrosine kinase inhibitors such as imatinib and erlotinib in gastrointestinal stromal tumors and non-small cell lung cancer, suggesting that NFκB inhibitors such as quinacrine may be therapeutically useful in combination with receptor tyrosine kinase inhibitors. Methylation of specific lysine residues of the pro-oncogenic transcription factors NFκB and STAT3 are important for their functions and thus present attractive targets for drug development. There is much recent information concerning the sites of methylation, the enzymes that carry out the reactions, and the functional consequences of methylation. This seminar is hosted by the Cancer Cell Signaling Program, but all are encouraged to attend. CME credit is available. Office of Cancer Centers Learning Series Webinar: Opportunity for CTSU Support for Collaborative Multi-Center Phase 2 Trials Led by NCI-Designated Cancer Centers and SPOREs Please plan on participating in the next Office of Cancer Centers Learning Series Webinar on Monday, December 5 from 2-3:30 pm. The presentation will describe an opportunity for Cooperative Group, NCI Designated Cancer Center, and Specialized Programs of Research Excellence (SPORE) investigators to develop clinical trial collaborations through discussions in NCI's Scientific Steering Committees. For clinical trial collaborations requiring multi-center coordinating support that is not otherwise available through existing networks, NCI will prioritize requests for in-kind coordination support through its Cancer Trials Support Unit (CTSU). Featured speaker Raymond A. Petryshyn, PhD, Program Director of the Coordinating Center for Clinical Trials, will discuss the type of support available, eligibility criteria and the evaluation process for CTSU applications. FUNDING OPPORTUNITIES Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant The AACR Pathway to Leadership Grant is designed to build future leaders in the pancreatic cancer research community by supporting a highly promising early-career scientist in his/her postdoctoral or clinical research fellowship through the transition to an independent researcher. Applicants must have started a postdoctoral or clinical research fellowship on or after July 2, 2007 (i.e., must be in the first five years of a fellowship at the start of the grant term). Extended Deadline: November 29 Robert Wood Johnson Foundation Clinical Scholars Program The Robert Wood Johnson Foundation and the U.S. Department of Veterans Affairs collaborate to foster the development of physicians who will lead the transformation of Americans' health and health care through the Robert Wood Johnson Foundation Clinical Scholars program. These future leaders will conduct innovative research and work with communities, organizations, practitioners and policy-makers to address issues essential to the health and well-being of all Americans. Deadline: February 29, 2012 ANNOUNCEMENTS Vogelbaum and Peereboom Elected to Society for Neuro-Oncology Board of Directors The following Cancer Center members were recently elected to the Society for Neuro-Oncology Board of Directors: Dr. Michael Vogelbaum, Vice President, and Dr. David Peereboom, Medical Oncology Representative. The Society for Neuro-Oncology is the largest international scientific and professional multidisciplinary society focused on the science and treatment of central nervous system tumors. NCI Releases Revised Best Practices for Biospecimen Resources The NCI has announced the release of revised Best Practices for Biospecimen Resources. Originally released in 2007, this document identifies guiding principles defining state-of-the-science practices for biospecimen resources, promoting biospecimen and data quality, and supporting adherence to ethical and legal principles. This revised version incorporates more current and detailed recommendations, and responds to comments received from community stakeholders. Major revisions include: An interactive online format that allows greater flexibility and access to the information. New sections on conflicts of interest and the management and operation of biospecimen resources. Expanded recommendations related to custodianship and informed consent. Harmonization with current Federal guidance documents and international biospecimen organizations. Updated references throughout. Like the 2007 release, this version of the NCI Best Practices underwent scrutiny by experts within NCI and throughout the NIH. A draft version of the revised document was posted online for public comment and all the input received was considered in the final version of the document. Friends of Cancer Research, with the Support of Over 25 Leading Advocacy Organizations, Releases Report Identifying Comparative Effectiveness Research (CER) Priority Studies in Cancer Last week, Friends of Cancer Research released a new report, Expanding Comparative Effectiveness Research: Priority Areas in Oncology. The report is the outgrowth of the June 2011 Friends of Cancer Research conference that brought together key stakeholders from the entire cancer community. Over 40 initial topics were submitted for review and public input. The report describes specific areas of CER that could begin to improve the field of oncology. It contains 13 potential comparative effectiveness research studies in oncology that were identified by leaders of the cancer community and the Friends Comparative Effectiveness Research Advisory Committee, that could begin to be addressed by public and private-sector funders of research. These entities include the publicly funded Patient-Centered Outcomes Research Institute, other government agencies, academic research institutions and the private sector.	EVENTS All events are open to anyone interested in attending November 14 Skeletal Research Center Diego Correa, MD, PhD Senior Research Associate, Skeletal Research Center, Biology CWRU Topic:** BM-MSC/Pericytes: Gatekeepers Controlling Skeletal Metastasis 4 pm Millis 123 November 15 Hematology/Oncology Special Research Conference Robert Van Buren Emmons, MD Associate Professor, Medicine, BMT Program Temple University Topic: Stem Cell Transplant 2011 and the Way Forward 8 am Wearn 137 Cancer Biology Special Seminar Steven Lipkin, MD, PhD Associate Professor, Medicine and Genetic Medicine Cornell University Topic: The Chemokine 25 and Chemokine Receptor 9 Axis Suppresses Colon Cancer Invasion and Metastasis 11 am NC1-202 Cleveland Clinic Immunology Seminar Series Pamela Wearsch, PhD Assistant Professor, Pathology CWRU Topic: Optimization of the MHC Class I Peptide Repertoire 12 pm WRB 1-413 Pharmacology Seminar Steffi Oesterreich, PhD Associate Professor, Pharmacology and Chemical Biology University of Pittsburgh Topic: Endocrine Resistance in Breast Cancer- Genetics or Epigenetics 12 pm Webster Conference Room, SOM W331 November 16 Hematology and Oncology Division Research Conference canceled Immunology Visiting Professor Seminar Series Laurence Morel, PhD Director, Div. of Experimental Pathology University of Florida Topic: Dissection of the Murine Sle1 Lupus Susceptibility Locus 12 pm NC1-202 Cleveland Clinic November 17 Molecular and Microbiology Seminar Amanda Tomalka Rietsch Lab, Molecular and Microbiology CWRU Topic: Export Signals of the P. Aeruginosa Type III Secretion Translocator PopD AND Arne Rietsch, PhD Assistant Professor, Molecular and Microbiology CWRU Topic: Functional Interactions Among Translocator Proteins in the P. Aeruginosa Type III Secretion System 1 pm SOM W203 November 18 Hematology/Oncology Fellows Conference canceled Taussig Cancer Institute Grand Rounds Brandon Hayes-Lattin, MD Medical Director, Adolescent and Young Adult Oncology Program Oregon Health and Science University Knight Cancer Institute Topic: What's Different About Adolescents and Young Adults (AYA) With Cancer? 8 am R3/002-003 Cleveland Clinic Cancer Center Seminar Series George Stark, PhD Staff and Distinguished Scientist, Molecular Genetics, Lerner Research Institute Professor Emeritus, Genetics CWRU Topic: Novel NFκB and STAT Signaling Pathways Present Novel Targets for Drug Development in Cancer 12 pm BRB 105 Cancer Center Research in Progress Seminar Topic: TBD 4 pm WRB 3-136 Case CCC Calendar LRI Calendar



PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES
NCI Provocative Questions Project Deadline: November 14 Rita Allen Foundation Scholars Program Internal Deadline: November 14 AACR–Conquer Cancer Foundation of ASCO Young Investigator Translational Cancer Research Award Deadline: November 15 Cellular Molecular Imaging of Cancer Pilot Funding: Cancer Microenvironment Deadline Extended: November 22 Robert Wood Johnson Foundation Community Health Leaders Deadline: November 28 SU2C-PCF Prostate Dream Team Translational Cancer Research Grant LOI Deadline: November 28 Burroughs Wellcome Fund Collaborative Research Travel Grants Deadline: December 1 CTSC Core Utilization pilot program Deadline: December 1 Kimmel Scholar Award Deadline: December 1 Kimmel Translational Science Award Deadline: December 1 American Medical Association Seed Grant Research Program Deadline: December 5 2012 NIH Director's Transformative Research Awards LOI Deadline: December 12 Application Deadline: January 12, 2012 L'Oréal USA Fellowships For Women In Science Deadline: December 15 Lymphatic Research Foundation (LRF) Postdoctoral Fellowship Program Deadline: January 10, 2012	HHMI Medical Research Fellows Program Deadline: January 11, 2012 2012 CTSC Annual Pilot Grant Funding Mandatory LOI Deadline: January 15 Oncology Nursing Society Foundation Connie Henke Yarbro Excellence in Cancer Nursing Mentorship Award Deadline: January 15, 2012 Robert Wood Johnson Foundation Executive Nurse Fellows Deadline: January 18, 2012 Innovations for Health: Solutions that Cross Borders Deadline: February 13, 2012 Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC) Deadline: Open AACR Scholar-in-Training Awards - Other Conferences and Meetings Deadline: Open Case CCC Protocol Specific Research Support (PSRS) Deadline: Open International Union Against Cancer (UICC) International Cancer Technology Transfer Fellowships Application Deadline: Open International Waldenstrom's Macroglobulinemia Foundation (IWMF) Research Grant Program Application Deadline: Open NCI Short-Term Scientist Exchange Program Application Deadline: Open

NIH BULLETIN – Notices and Funding Opportunities NIH Competitive Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (R01) (PAR-12-010) NIH Competitive Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U01) (PAR-12-011)
Produced by: Gillian Irwin Todd 11100 Euclid Avenue, Wearn 149 Cleveland, Ohio 44106-5065 216-844-8317 phone 216-844-7832 fax gillian.irwin@case.edu	HELP US HELP YOU! If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to gillian.irwin@case.edu.